Comparative Pharmacology
Head-to-head clinical analysis: FEMSTAT 3 versus NYSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMSTAT 3 versus NYSTATIN.
FEMSTAT 3 vs NYSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butoconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to sterols in the fungal cell membrane, primarily ergosterol, altering membrane permeability and causing leakage of intracellular components, leading to fungal cell death.
Intravaginal cream: 1 applicatorful (5 g of 2% butoconazole nitrate) intravaginally at bedtime for 3 consecutive days.
Oral: 500,000 to 1,000,000 units (5-10 mL suspension) swish and swallow 3-4 times daily; Vaginal: 1 vaginal tablet (100,000 units) once or twice daily; Topical: Apply cream/ointment 2-3 times daily; duration depends on indication.
None Documented
None Documented
Clinical Note
moderateNystatin + Tranilast
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast."
Clinical Note
moderateNystatin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tolfenamic acid."
Clinical Note
moderateNystatin + Nimesulide
"The risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide."
Clinical Note
moderateNystatin + Risedronic acid
The terminal elimination half-life of butoconazole following topical vaginal administration is approximately 21-24 hours. This prolonged half-life supports once-daily dosing for 3 days in the treatment of vulvovaginal candidiasis.
Due to minimal systemic absorption, a terminal elimination half-life is not clinically relevant. In vitro plasma degradation half-life is approximately 1.5 hours, but this is not applicable in vivo.
Following topical vaginal administration of butoconazole nitrate, approximately 5% of the dose is absorbed systemically. The absorbed fraction is primarily metabolized in the liver and excreted via the biliary/fecal route. Renal excretion accounts for less than 3% of the administered dose.
Nystatin is not absorbed from the gastrointestinal tract after oral administration; virtually 100% of the ingested dose is excreted unchanged in the feces. After topical application, systemic absorption is negligible; any absorbed drug is excreted via bile and feces (<1% renal).
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Nystatin is combined with Risedronic acid."